We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Selective Ribosome-Targeting Drug with Low Ototoxicity Could Provide Safer Treatment Option for Leishmaniasis

By LabMedica International staff writers
Posted on 02 Sep 2015
In a multidisciplinary biological study, researchers have shed new light on the mechanism of action of a potent drug for leishmaniasis, the natural aminoglycoside paromomycin (PAR), and have found that a new synthetic derivative of PAR may provide a far lower risk of irreversible hearing loss side-effects, probably via its more selective targeting of cytosolic (vs. More...
mitochondrial) ribosomes.

The limited arsenal of drugs currently available for leishmaniasis therapy, coupled with the rather fast emergence of parasite resistance, presents a dire public health concern. A promising approach is the delineation of new cellular drug-targets through mechanistic studies. Data from structural, biochemical, and pathological experiments are valuable for rational design and development of new potential therapeutic agents. The leishmanial ribosome is one potential target of antileishmanial therapeutics, especially for derivatives belonging to the important aminoglycosides (AG) family.

In the new study, a team of researchers, led by Timor Baasov, professor at the Technion - Israel Institute of Technology (Haifa, Israel), investigated the structural basis for the targeting of leishmanial ribosomes by AGs and performed comparative testing of the potential clinical effectiveness and side-effects of new (semi-) synthetic derivatives of PAR. The study was a collaboration of researchers from the Technion, the Weizmann Institute of Science (Rehovot, Israel), the Hebrew University-Hadassah Medical School (Jerusalem, Israel), and the University of Michigan Medical School (Ann Arbor, MI, USA).

PAR, a broad-spectrum antibiotic, is highly efficient in treating life-threatening visceral leishmaniasis (VL). In 2007, the World Health Organization (WHO) listed PAR injection for VL as an essential medication due to its high potency, accessibility, and affordability in highly endemic countries. Also, a new combination therapy of PAR given with liposomal amphotericin B has shown potential to be short, safe, and effective, and would help prevent development of drug resistance and lower cost compared to treatment with liposomal amphotericin B alone.

However, PAR can have severe ototoxic side-effects. In mild cutaneous leishmaniasis (CL), this toxicity is less problematic as single lesions are generally treated topically, however in CL where multiple lesions are present, or in mucocutaneous leishmaniasis and VL where PAR or other AGs are given systemically, toxicity often becomes a serious problem.

While much focus has been given to exploration of PAR activities in bacteria, its mechanism of action in Leishmania has received relatively little attention. In the new study, the researchers present, for the first time, X-ray crystallography results of PAR bound in complex with a ribosomal RNA (rRNA) model mimicking two leishmanial cytosolic ribosomal binding sites (ribosomal “A-sites”). They also evaluated inhibitory actions on leishmanial growth and ribosome function, as well as effects on mammalian auditory sensory cells, by comparing structurally related AGs. The results provided insights into the structural elements important for AG inhibitory activities and selectivity for leishmanial cytosolic ribosomes, and highlighted a novel synthetic derivative of PAR, compound-3, as a prospective candidate for effective treatment. In preliminary in vivo experiments in a guinea pig model, compound-3 exhibited low auditory toxicity compared to PAR, and so could eliminate a major drawback that limits clinical use of PAR and other currently available AGs.

The study, by Shalev M, et al., was reported online, ahead of print, August 11, 2015, in the journal Nucleic Acids Research.

Related Links:

Technion - Israel Institute of Technology




Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.